All In Biotech

Drug Trial Radar · NCT06529445

Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Aug 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Jul 22, 2024

Primary completion

Aug 26, 2024

Study completion Aug 26, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate Food effect and Relative bioavailability of VC004 Capsules in healthy subjects

Conditions

  • Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

Interventions

  • High Dose VC004 CapsulesDrug

    VC004 Capsules qd per period, for two periods

  • Median Dose VC004 CapsulesDrug

    VC004 Capsules qd per period, for two periods

  • Low Dose VC004 CapsulesDrug

    VC004 Capsules qd per period, for two periods

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax)Time frame: Day1-Day7
  2. Peak time(Tmax)Time frame: Day1-Day7
  3. Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC)Time frame: Day1-Day7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongda Hospital,Affiliated to Southeast University

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.